HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].

Abstract
We prospectively studied the usefulness of chlormadinone acetate (CMA) as an alternative therapy for prostate cancer relapse after combined androgen blockade (CAB) therapy. Sixteen patients with relapsed prostate cancer after treatment with CAB, including surgical or medical castration and nonsteroidal antiandrogens, 80 mg bicalutamide daily or 375 mg flutamide daily, were enrolled. After discontinuing the antiandrogen for evaluating the patient for the antiandrogen withdrawal syndrome, we administered 100 mg CMA daily as alternative antiandrogen and estimated its effect. Four patients showed a > or = 50% decline in prostate-specific antigen (PSA) levels and another 4 patients showed a < 50% decline in PSA levels but residual 8 patients showed no decline in PSA levels. In 8 patients with a decline in PSA levels, the median duration of alternative CMA therapy was 11.4 months. Patients with a PSA level of < 1 ng/ml at the start of CMA therapy showed the tendency of decline in PSA levels. In contrast, patients with a nadir PSA level of > or = 0.2 ng/ml during pretreatment showed no effectiveness of the alternative CMA therapy. The alternative CMA therapy may be useful in a part of patients with prostate cancer relapse after CAB therapy.
AuthorsHidetoshi Ehara, Seichi Katoh, Keita Nakane, Taku Katoh, Toshihiko Takada, Keitaro Kojima, Shingo Kamei, Noriyasu Hagiwara, Kazuya Yuhara, Yoshito Takahashi, Yoshinori Fujimoto, Shigeru Fujihiro, Yuhsuke Kanimoto, Takashi Deguchi
JournalHinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 55 Issue 4 Pg. 199-203 (Apr 2009) ISSN: 0018-1994 [Print] Japan
PMID19462824 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Androgen Antagonists
  • Chlormadinone Acetate
Topics
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists (therapeutic use)
  • Chlormadinone Acetate (therapeutic use)
  • Combined Modality Therapy
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy)
  • Prospective Studies
  • Prostatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: